Feds and Lilly Make Their Case to Federal Judge in Key Hearing Today

U.S.District Judge Sarah Evans Barker held a hearing today in drug manufacturer Eli Lilly's 340B contract pharmacy lawsuit against HRSA.

Attorneys for the government and drug manufacturer Eli Lilly dueled over the legality of 340B contract pharmacy requirements during a hearing before a federal district judge in Indianapolis today.

Stakeholders are watching the Lilly case closely because, given

Read More »

Key GOP Congressman Opposed 340B Amendment to Spending Bill During Committee Hearing

Rep. Michael Burgess (R-Texas) this week cited ongoing 340B contract pharmacy litigation in cautioning against amending federal spending legislation to rebuke six drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.

An influential Republican congressman on Monday cautioned against amending federal spending legislation to rebuke six drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.

During a July 26 U.S. House Rules Committee hearing, Rep. Michael

Read More »

In AstraZeneca’s 340B Lawsuit, Focus Shifts to HRSA’s May 17 Violation Letter

AstraZeneca and the federal government have filed a new round of briefs in the drug manufacturer’s 340B contract pharmacy lawsuit.

AstraZeneca and the federal government have filed a new round of briefs in the drug manufacturer’s 340B contract pharmacy lawsuit, this round focused on the government’s May 17 letter telling the company its contract pharmacy actions are illegal.

Read More »

340B Won’t be Overlooked if There’s a Grand Bargain on Drug Pricing, Analyst Predicts

340B “will not be overlooked” if the drug industry strikes a grand bargain with Congress and the Biden administration on lowering drug prices, biopharma policy analyst Michael McCaughan predicts.

The 340B program “will not be overlooked” if the drug industry strikes a grand bargain with Congress and the Biden administration on lowering drug prices, biopharma policy analyst Michael McCaughan predicted this week during a talk on drug

Read More »

Kalderos Urges Feds to Protect Hospitals from Losing 340B Eligibility During Pandemic

Drug industry vendor Kalderos is urging leaders in Washington to temporarily shield hospitals from losing their 340B eligibility during the COVID-19 pandemic.

Drug industry vendor Kalderos is urging leaders in Washington to temporarily shield hospitals from losing their 340B eligibility during the COVID-19 pandemic.

“Kalderos is urging a rapid federal response to protect these hospitals,” the company said in a

Read More »

Retired Senator Enzi, Who Backed 340B Inquiries, Dies Following Accident

Retired U.S. Sen. Mike Enzi (R-Wy.), who co-led inquiries into stewardship of the 340B program while in Congress, has died at age 77.

Retired U.S. Sen. Mike Enzi (R-Wy.), who co-led inquiries into stewardship of the 340B program while in Congress, died on Monday after being injured in a bicycle accident in his hometown of Gillette, Wyo. He was 77.

Enzi

Read More »

Building the Case for Dedicated 340B Program Management

SPONSORED CONTENT

Finance guys like myself often have the reputation of being unwilling to spend money. However, we can always be convinced to invest in activities with a high likelihood of return.

The financial pressures of the last year have underscored the importance of the 340B program and its impact on hospital finances. Against the backdrop of cost-cutting measures across the organization, it may seem counterintuitive to

Read More »

News Alert: U.S. House Votes to Highlight Need to Halt Pharma’s “Unlawful” 340B Actions

U.S. Rep. Abigail Spanberger (D-Va.) said her successful amendment today to a spending bill sends big pharma the message "Stop hiking drug prices on consumers and discriminating against our 340B providers and pharmacies."

The U.S. House voted this evening “to highlight the need to protect the integrity of the 340B program by halting pharmaceutical manufacturers’ unlawful actions that have resulted in overcharges to 340B covered entities.”

Reps. Abigail Spanberger (D-Va.) and

Read More »

HRSA Posts Novartis Notice About 340B Refunds on a Top-Selling Drug—With Contract Pharmacy Strings Attached (Updated)

Novartis is putting conditions on refunds to 340B hospitals for overcharges on its second-best selling drug.

UPDATE Tuesday, July 27, 2021, 1:45 p.m. Eastern—Drug manufacturer Novartis provided the following statement:

“Novartis recently notified the Health Resources and Services Administration (HRSA) that we inadvertently neglected to offer the 340B ceiling price to covered entity types

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors